↓ Skip to Main Content

the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Search for:

Log in | Register

Main Navigation

english
thasso
thasso: post
thasso: interactions
thasso: resources
thasso: academy
thasso: about
donations $
Cookie Policy (EU)

Home › Posts tagged Erdheim-Chester Disease (ECD)

Tag: Erdheim-Chester Disease (ECD)

FDA-cleared genomic profiling tests to guide cancer treatment

By Joseph Gut - thasso Posted on December 25, 2017 Posted in Allelic Variant, Companion Test, Diagnostic, Genetic Background, In The Press, New Research, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine Tagged with Basket Clinical Trial, Centers for Medicare & Medicaid Services (CMS), Companion Test, Erdheim-Chester Disease (ECD), FoundationOne CDx (F1CDx), MSK-IMPACT Test, Thasso Post, Theragenomic Medicine, Vemurafenib [Zelboraf]

FDA-cleared genomic profiling tests to guide cancer treatment

December 25, 2017 – The American Food & Drug Administration (FDA) has approved two genetic tests to identify genetic alterations in tumors. The FoundationOne CDx (F1CDx) genomic test and the MSK-IMPACT Tumor Profiling test both can help to guide physicians in …

FDA-cleared genomic profiling tests to guide cancer treatment Read more »

Vemurafenib (Zelboraf) for BRAF V600E positive Erdheim-Chester Disease (ECD)

By Joseph Gut - thasso Posted on December 21, 2017 Posted in Allelic Variant, Genetic Background, Genetic Predisposition, New Indication Approval, Personalized Medicine, Rare Diseases, Regulatory Announcement, Targeted Therapy, Thasso Post, Theragenomic Medicine Tagged with American Food & Drug Administration (FDA), Blood Cancer, BRAF V600E, Cancer, Erdheim-Chester Disease (ECD), Nwe Indication, Rare Disease, Thasso Post, Theragenomic Medicine, Vemurafenib [Zelboraf]

Vemurafenib (Zelboraf) for BRAF V600E positive Erdheim-Chester Disease (ECD)

Dezember 21, 2017 – Erdheim–Chester disease ((ECD), also known as Erdheim–Chester syndrome or polyostotic sclerosing histiocytosis) is a form of a bone marrow borne blood cancer. It is a rare disease characterized by the abnormal multiplication of a specific type …

Vemurafenib (Zelboraf) for BRAF V600E positive Erdheim-Chester Disease (ECD) Read more »

In/Out

Log in

Optional: Social Subscribe/Login

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you. Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci. Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank. Abbiamo bisogno del tuo aiuto. Si prega di sostenere lo sviluppo di thasso attraverso donazioni. Grazie. Nós precisamos da sua ajuda. Por favor, apoie o desenvolvimento de thasso através de doações. Obrigada. Necesitamos tu ayuda. Por favor apoye el desarrollo de thasso con donaciones. Muchas gracias.

thasso: conditions

thasso: newest tweets

Tweets by thasso_info

FDA press releases

FDA Roundup: June 2, 2023 June 2, 2023
FDA Conducts Retailer Inspection Blitz, Cracks Down on Illegal Sales of Popular Disposable E-cigarettes May 31, 2023
FDA Roundup: May 30, 2023 May 30, 2023
FDA Proposes New, Easy-to-Read Medication Guide for Patients, Patient Medication Information May 30, 2023
FDA Roundup: May 26, 2023 May 26, 2023

FDA MedWatch

FAQs on Philips Respironics Ventilator, BiPAP Machine, and CPAP Machine Recalls June 2, 2023
UPDATE: Certain Philips Respironics Ventilators, BiPAP Machines, and CPAP Machines Recalled Due to Potential Health Risks: FDA Safety Communication June 2, 2023
2023 Safety Communications May 30, 2023
FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions. May 26, 2023
SD BioSensor, Inc. Recalls Certain Pilot COVID-19 At-Home Tests for Potential Bacteria Contamination May 25, 2023

EMA Press releases

Progress with EU-US mutual recognition agreement for inspections for veterinary medicines, , 31/05/2023 May 31, 2023
Global regulators agree on way forward to adapt COVID-19 vaccines to emerging variants, , 30/05/2023 May 30, 2023
EMA business hours over Whit Monday, 29 May, , 26/05/2023 May 26, 2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 May 2023, CHMP, 26/05/2023 May 26, 2023
EMA recommends revocation of authorisation for sickle cell disease medicine Adakveo, CHMP, 26/05/2023 May 26, 2023

random genetics

Risk factor for psychiatric disorders has different effects depending on sex, finds research June 2, 2023
The protein FKBP51 is considered a risk factor for psychiatric disorders. However, for the first time, new research results have shown positive effects. Instead of making people anxious or impairing their ability to think, the protein can have the opposite effect and thus promote resilience. The effect it has depends on the type of cells […]
Study: Early rhythm control is safe, effective in atrial fibrillation patients irrespective of genetic predisposition June 2, 2023
A sub-study analysis of the EAST—AFNET 4 trial revealed how genetic risk for atrial fibrillation (AF) and stroke interacts with early rhythm control therapy: Early rhythm control reduces cardiovascular events in patients with AF across the spectrum of genetic AF and stroke risks. The findings were published in the journal Cardiovascular Research.
Research unveils dynamic human eye architecture: A breakthrough in ophthalmology June 1, 2023
The RPE and choroid, located behind the human retina, are fundamental to vision, playing a myriad of roles from light absorption to providing oxygenated blood to the photoreceptor cells. However, our understanding of the gene expressions within these cells and how they contribute to retinal diseases has been limited.
Reducing seizures after brain tumor treatment June 1, 2023
Northwestern Medicine investigators have shown that inhibiting a mutated gene can reduce seizure activity in adult-type diffuse gliomas, according to a study published in the Journal of Clinical Investigation.
How mutations to a key liver cancer pathway contribute to tumor progression June 1, 2023
New Peter Mac research recently published in Proceedings of the National Academy of Sciences (PNAS) has discovered a fundamental breakthrough related to the development of liver cancer.

Recent Comments

Joseph Gut - thasso on Is there pre-emptive genotyping to avoid adverse drug effects (ADRs)?: “Just testing. https://www.alphamannosidosis.com/en/for-patients-caregivers/disease-information/?utm_source=google&utm_medium=cpc&utm_campaign=AlphamannSearch_Paziente2020&gclid=EAIaIQobChMI2Pv7wNaC_AIVWud3Ch1J8AMPEAAYAiAAEgJGI_D_BwE/” Dec 18, 08:50
Joseph Gut - thasso on Including Africa in the research on rare genetic diseases: A must!: “The genetic diversity of African populations with respect to rare genetic diseases will help to better understand the mechanisms behind…” Dec 18, 04:09
Joseph Gut - thasso on The sixth sense: Are there genes associated with it?: “Does this now work as intended?” Dec 18, 03:55
David Walliams on Is genetic testing of value for ALS patients?: “CURED FROM GENITAL HERPES More than 5 years ago I was in pain with this deadly herpes virus, A few…” Nov 7, 16:08
Raul Malkovic on Is genetic testing of value for ALS patients?: “HOW MY WIFE GOT CURED FROM ALS Below is how i got a cure for my wife who suffered from Amyotrophic Lateral Sclerosis…” Nov 6, 21:18

Tag Cloud

Adverse Drug Reaction (ADR) African American Allelic Variant Allelic Variants American Food & Drug Administration (FDA) American Food & Drug Administration (FDA) Boxed Warning Breast Cancer Canagliflozin (Invokana) Cancer Children Committee for Medicinal Products for Human Use (CHMP) Companion Test Covid-19 Disease Diabetes Drug Induced Liver Injury (DILI) Epidermal Growth Factor Receptor (EGFR) Ethnicity European Medicine Agency (EMA) European Medicines Agency (EMA) Food and Drug Administration (FDA) Gene Therapy Genetic Background Genetic Predisposition Genetic Testing Genotype Health Canada Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab [Keytruda] Personalized Medicine Phenotype Progressive Multifocal Leukoencephalopathy (PML) Rare Disease Risk Evaluation and Mitigation Strategy (REMS) SARS-CoV-2 Schizophrenia Sildenafil [Viagra] Stevens Johnson Syndrome [SJS] Targeted Therapy ThassoBase Thasso Post Theragenomic Medicine Toxic Epidermal Necrolysis (TEN) Type 2 Diabetes Vemurafenib [Zelboraf]

Meta

Register
Log in
Entries feed
Comments feed
WordPress.org

© 2023 Thasso | Powered by Responsive Theme

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage vendors Read more about these purposes

View preferences

{title} {title} {title}